Head-to-head · Cost-Efficiency Index
Framework vs LaSara Medical Group
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Framework
Cost-first shoppers who want doctor-guided treatment selection with a named pharmacy, if you can accept learning the price only after intake.
Visit FrameworkLaSara Medical Group
Shoppers who want a hybrid in-person/telehealth GLP-1 option in Southern California and are comfortable prepaying a year for the lowest rate.
Visit LaSara Medical GroupThe verdict
Framework and LaSara Medical Group tie on the Cost-Efficiency Index at 45/100, so neither wins outright on the numbers. For most shoppers we'd start with Framework (ranked #463, a hair above #465) — Cost-first shoppers who want doctor-guided treatment selection with a named pharmacy, if you can accept learning the price only after intake. But LaSara Medical Group is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Framework.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Framework | LaSara Medical Group |
|---|---|---|
| Cost-Efficiency Index | 45/100 | 45/100 |
| Semaglutide / mo | Not disclosed | $299/mo (starting dose, compounded) |
| Tirzepatide / mo | Not disclosed | $399/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | — | $3,588 |
| Tirzepatide / yr (modeled) | — | $4,788 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #463 | #465 |
Framework
45/100Where the value is
- The compounding pharmacy partner is named, which most of this field does not do
- Treatment selection is doctor-guided rather than a fixed product menu
- US-licensed clinicians and a 503A pharmacy pathway
The tradeoffs
- No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
- The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
LaSara Medical Group
45/100Where the value is
- Full, clean 4-tier pricing tables published for both drugs with exact dollar totals at every commitment length — real transparency, no gating behind intake
- Named clinical leadership: Medical Director Dr. Sunil Kurup and Founder/CEO John Snedegar
- Rare hybrid model — national telehealth plus an actual in-person Southern California option, alongside a broader hormone/peptide menu (TRT, NAD+, sermorelin, B12, enclomiphene)
The tradeoffs
- The lowest advertised per-month figures ($233 sema / $325 tirz) require a full 12-month prepay charged upfront ($2,795 / $3,895 at once) — the real month-to-month price is $299 / $399, 28-33% higher
- States served are not disclosed anywhere on the pricing pages despite the 'national telehealth' claim
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.